Introduction: Addressing Immune System Safety Risks, Regulatory Mandates, and Biologic-Specific Toxicity Pain Points
For pharmaceutical R&D directors, toxicologists, and regulatory affairs managers, immunotoxicity testing has become a critical component of nonclinical safety assessment—particularly for immunomodulatory drugs, biologics, gene therapies, and small molecules that may unintentionally interfere with immune function. Immunosuppression increases infection risk (opportunistic infections, reactivation of latent viruses), immunostimulation triggers cytokine release syndrome (CRS) and autoimmune reactions, and hypersensitivity leads to anaphylaxis or drug-induced lupus. The tragic TGN1412 clinical trial (2006, catastrophic cytokine storm) and recent CAR-T therapy CRS events have heightened regulatory scrutiny (FDA, EMA, ICH S8, ICH S6, ICH S9). Immunotoxicity testing identifies potential adverse immune effects—suppression (reduced T/B cell counts, impaired antibody response), stimulation (cytokine release, autoantibodies, hypersensitivity), and autoimmunity (anti-drug antibodies, tissue-directed antibodies). As immunomodulatory pipelines expand (checkpoint inhibitors, bispecific antibodies, CAR-T, mRNA vaccines, gene therapies), demand for specialized immunotoxicity CRO services is accelerating. Global Leading Market Research Publisher QYResearch announces the release of its latest report “Immunotoxicity Testing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Immunotoxicity Testing market, including market size, share, demand, industry development status, and forecasts for the next few years.
For toxicology outsourcing managers, CMC directors, and biopharma investors, the core pain points include achieving regulatory compliance (ICH S8, ICH S6, FDA guidance, EMA guideline), selecting appropriate in vivo (mouse, rat, non-human primate) or in vitro (human cell-based, immune cell panel) models, and managing testing timelines (4–12 months for comprehensive immunotoxicity package). According to QYResearch, the global immunotoxicity testing market was valued at US$ 5,538 million in 2025 and is projected to reach US$ 12,610 million by 2032, growing at a CAGR of 12.7% .
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097976/immunotoxicity-testing
Market Definition and Core Capabilities
Immunotoxicity testing evaluates whether a substance—drug, biologic, chemical, or medical device material—interferes with normal function, regulation, or integrity of the immune system. Core capabilities:
- Immunosuppression Testing: Reduced immune cell counts (T cells, B cells, NK cells, neutrophils, monocytes, dendritic cells), impaired antibody response (T-cell dependent antibody response – TDAR, keyhole limpet hemocyanin – KLH, sheep red blood cells – SRBC), reduced T-cell proliferation (mixed lymphocyte reaction – MLR, mitogen stimulation), reduced NK cell activity (⁵¹Cr release assay). Used for immunosuppressive drugs (calcineurin inhibitors, mTOR inhibitors, corticosteroids), chemotherapy, and biologics targeting immune checkpoints (PD-1/PD-L1, CTLA-4).
- Immunostimulation Testing: Cytokine release (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IL-22, IFN-γ, TNF-α, GM-CSF) in human whole blood or PBMCs (peripheral blood mononuclear cells). Cytokine release syndrome (CRS) risk assessment for T-cell engagers (BiTEs, DARTs), CAR-T cells, bispecific antibodies, and immunostimulatory antibodies (CD3, CD28, 4-1BB, OX40). Hypersensitivity testing (anaphylaxis, skin sensitization, respiratory sensitization). Autoimmunity (anti-nuclear antibodies – ANA, anti-dsDNA, anti-histone, anti-phospholipid).
- In Vivo Testing (40–45% of revenue, largest segment): Animal models (mouse, rat, dog, non-human primate) for regulatory submission (ICH S8, ICH S6). TDAR (KLH, SRBC) – gold standard for immunosuppression assessment. Lymphocyte phenotyping (flow cytometry: CD3, CD4, CD8, CD19, CD20, CD56, CD16). Natural killer (NK) cell activity. Host resistance models (Listeria monocytogenes, influenza virus, Candida albicans, Plasmodium yoelii). In vivo testing required for IND/NDA/BLA submission.
- In Vitro Testing (50–55% of revenue, fastest-growing at 13–14% CAGR): Human cell-based assays (PBMCs, whole blood, isolated immune cell subsets) for early screening, mechanistic studies, and 3Rs (reduction, refinement, replacement of animal testing). Cytokine release assays (CRA) – soluble cytokine measurement (Luminex, MSD, ELISA). T-cell proliferation (CFSE dilution, Ki67). B-cell activation (CD69, CD86, CD40, MHC-II). Dendritic cell maturation (CD80, CD83, CD86, CD40, MHC-II). In vitro testing used for candidate selection, mechanistic understanding, and safety margin assessment.
Market Segmentation by Application
- Biotechnology (45–50% of revenue, fastest-growing at 13–14% CAGR): Biologics – monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), bispecific antibodies, fusion proteins, cytokines (IL-2, IFN-α, GM-CSF), growth factors, enzyme replacement therapies. Cell and gene therapies – CAR-T, TCR-T, NK, CAR-NK, AAV vectors, lentiviral vectors. Immunomodulatory biologics require extensive immunotoxicity assessment (CRS, immunosuppression, immunogenicity). Early-stage biotech outsources to CROs (Charles River, Eurofins, BioAgilytix, Altasciences, IQVIA, Nelson Labs).
- Pharmaceutical Industry (40–45% of revenue, largest segment): Small molecule drugs – immunosuppressants (cyclosporine, tacrolimus, sirolimus, mycophenolate), chemotherapeutics (cyclophosphamide, methotrexate, azathioprine), JAK inhibitors (tofacitinib, upadacitinib), checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab). ICH S8 (Immunotoxicity Studies for Human Pharmaceuticals) requires immunotoxicity assessment for all new drugs with potential immune effects.
- Others (10–15% of revenue): Chemicals (pesticides, industrial chemicals, environmental contaminants), medical devices (biomaterials, implants, drug-eluting stents), food additives, cosmetics (EU ban on animal testing – in vitro alternatives).
Technical Challenges and Industry Innovation
The industry faces four critical hurdles. Predictivity of in vitro assays for in vivo immunotoxicity (e.g., cytokine release assays vs. clinical CRS) has variable sensitivity/specificity (60–90%). False negatives (missed CRS risk) lead to clinical trial failures (TGN1412). False positives (unnecessary risk flags) kill promising candidates. Advanced models (humanized mice, MPS – microphysiological systems, organ-on-chip) improve predictivity but cost 10–100× more. Species selection for in vivo testing (rodent vs. non-human primate) for biologics with human-specific targets (cross-reactivity). Many biologics (mAbs, CAR-T) only cross-react with non-human primates (cynomolgus monkey, rhesus macaque), increasing cost ($50–500k per study) and ethical concerns. Cytokine release syndrome (CRS) risk assessment for T-cell engagers and CAR-T cells requires specialized assays (soluble cytokine panel, cell surface activation markers, proliferation). Standard assays may not detect low-affinity T-cell activation (false negatives). Regulatory harmonization across FDA, EMA, PMDA, NMPA (ICH S8, ICH S6, FDA guidance, EMA guideline) for immunotoxicity testing requirements (TDAR mandatory, lymphocyte phenotyping, NK activity, host resistance) varies in interpretation. Sponsors often design studies to meet multiple agency expectations (increased scope, cost).
独家观察: CAR-T and BiTE Immunotoxicity Testing Fastest-Growing Segment
An original observation from this analysis is the double-digit growth (15–16% CAGR) of immunotoxicity testing for CAR-T therapies (Kymriah, Yescarta, Breyanzi, Abecma, Carvykti) and bispecific T-cell engagers (BiTEs: Blincyto, Amgen’s pipeline) . CAR-T and BiTEs activate T-cells against tumor antigens, but can trigger severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Preclinical immunotoxicity assessment includes cytokine release assays (IL-6, IFN-γ, TNF-α, IL-2) in human whole blood or PBMCs, T-cell activation markers (CD25, CD69, CD137), and proliferation assays (CFSE, Ki67). In vivo testing in humanized mice (NSG, NOG) engrafted with human immune cells (PBMCs, CD34+ HSC) to model CRS. CAR-T/BiTE immunotoxicity testing projected 30%+ of market revenue by 2030 (vs. 15% in 2025). Additionally, mRNA vaccine immunotoxicity (COVID-19, influenza, RSV, personalized cancer) is an emerging segment (10–12% CAGR). mRNA-LNP formulations can activate innate immunity (TLR3, TLR7, TLR8, RIG-I, MDA5), causing cytokine release (IL-1β, IL-6, TNF-α, IFN-α) and reactogenicity (fever, chills, myalgia). Preclinical immunotoxicity testing (in vitro cytokine release in human PBMCs, in vivo cytokine profiling in mice) required for IND filing.
Strategic Outlook for Industry Stakeholders
For CEOs, outsourcing managers, and biopharma investors, the immunotoxicity testing market represents a high-growth (12.7% CAGR), regulatory-mandated opportunity anchored by immunomodulatory biologics (checkpoint inhibitors, bispecifics, CAR-T), gene therapies, and mRNA vaccines. Key strategies include:
- Investment in human cell-based in vitro assays (PBMC, whole blood, co-culture, microphysiological systems) for early candidate screening (reduce animal use, predict clinical CRS).
- Development of humanized mouse models (NSG, NOG, MISTRG) for in vivo immunotoxicity assessment of human-specific biologics (CAR-T, T-cell engagers, mAbs).
- Expansion into CAR-T and BiTE immunotoxicity testing (cytokine release, T-cell activation, neurotoxicity biomarkers) for oncology pipelines.
- Geographic expansion into Asia-Pacific (China, South Korea, Japan) for CRO outsourcing (biologics, cell/gene therapies) and North America/Europe for regulatory submissions.
Companies that successfully combine in vitro cytokine release assays, humanized mouse models, and regulatory expertise (FDA, EMA, PMDA, NMPA) will capture share in a $12.6 billion market by 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
